SISVEL
A new agreement between Nordic Semiconductor and patent pool administrator Sisvel for the licensing of standard essential patents (SEPs) reading on LTE-M and NB-IoT cellular technology has been announced. The agreement creates a framework for easy and transparent access to the LTE-M and NB-IoT radio technology standards for a diverse range of IoT applications.
Specifically, the initiative provides a simple, efficient way for IoT device makers to obtain end-product licences from more than 30 patent owners holding LTE-M and NB-IoT SEPs, through Nordic as the cellular module supplier.
The agreement addresses the challenges posed by the diversity within the cellular IoT market, in which a multitude of companies - from startups to established corporations - are innovating. The wide range of significant initiatives being rolled out in areas such as smart-health, smart-energy, smart-cities and asset-tracking are currently at risk of stalling because of the lack of predictability and transparency in the access to and the cost of SEP licensing.
By offering standardised licences the agreement will reduce business uncertainty and the possibility of litigation. This will allow companies to focus on what they do best - developing new, innovative products and services for the IoT market.
"Nordic Semiconductor has always been at the forefront of wireless technology and we understand the importance of accessible and standardised licensing for the advancement of the IoT industry," comments Øyvind Birkenes, Nordic’s EVP Long Range. "We believe that this solution is a significant step towards a more efficient future for cellular IoT development."
"We are thrilled to have a unique licensing programme for cellular IoT backed by more than 30 patent owners and we believe this new agreement with Nordic addresses a critical need in the IoT ecosystem," says Sisvel CEO Mattia Fogliacco. "Our goal is to create a balanced and transparent licensing environment that supports innovation and growth for all stakeholders."
“We have worked hard with Sisvel and the SEP owners in its pool over the last year to broker this agreement because the IoT market urgently needs transparency and predictability,” says Kristian Sæther, Nordic’s Product Director – Cellular IoT. “Existing SEP licensing in the IoT space is up-in-the-air, putting countless SMEs across the globe developing wireless products in limbo. This new agreement offers efficiency and predictability to our customers. We look forward to seeing our peers and competitors recognise the importance of this work, and joining the pool solution, so that the entire cellular IoT market can operate with more predictability, and on a level playing field.”
About Sisvel
Sisvel is driven by a belief in the importance of collaboration, ingenuity and efficiency to bridge the needs of patent owners and those who wish to access their technologies. In a complex and constantly evolving marketplace, our guiding principle is to create a level playing field with the development and implementation of flexible, accessible, commercialisation solutions.
About Nordic Semiconductor
Nordic Semiconductor is a complete end-to-end wireless connectivity solutions provider, with a world-leading position in Bluetooth Low Energy, and an emerging leader in Cellular IoT, NR+, and Wi-Fi wireless technologies, Matter, Thread, Zigbee, and power management. The company’s low power wireless solutions enable millions of IoT devices to connect. Using Nordic’s innovation, its customers and partners across the globe are changing societies and lives for the better by powering smarter, safer, and more sustainable solutions. Nordic’s world-class hardware, software, and development tools are amongst the most advanced in the world, and the company deliver a complete developer experience by offering ultra-low power wireless solutions that are easy to implement, with the best possible support.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509154129/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom